Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
The present invention relates to compounds and methods which may be useful as treatments of diseases.
1. A method of increasing percentage of ejection fraction and increasing percentage of fraction shortening in a patient with heart failure, the method comprising the administration, to a patient in need thereof, of a therapeutically effective amount of between about 2 mg/kg/day and about 30 mg/kg/day of a compound for treating the heart failure chosen from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. The method as recited in claim 1 , wherein said compound has the structural formula:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the improved ejection fraction and fraction shortening are measured by echocardiography.
4. The method of claim 1 , wherein the therapeutically effective amount is between about 15 mg/kg/day and about 30 mg/kg/day.
5. The method of claim 4 , wherein the therapeutically effective amount is about 15 mg/kg/day.
6. The method of claim 4 , wherein the therapeutically effective amount is about 30 mg/kg/day.
7. The method of claim 1 , wherein the administration is oral.
8. The method of claim 1 , wherein the administration has a duration of at least about eight weeks.
9. The method of claim 2 , wherein the improved ejection fraction and fraction shortening are measured by echocardiography.
10. The method of claim 9 , wherein the therapeutically effective amount is between about 15 mg/kg/day and about 30 mg/kg/day.
11. The method of claim 10 , wherein the therapeutically effective amount is about 15 mg/kg/day.
12. The method of claim 10 , wherein the therapeutically effective amount is about 30 mg/kg/day.
13. The method of claim 2 , wherein the administration is oral.
14. The method of claim 2 , wherein the administration has a duration of at least about eight weeks.
15. A method of treating heart failure comprising the oral administration, to a patient in need thereof, of between about 8 mg/kg/day and about 30 mg/kg/day of
or a pharmaceutically acceptable salt thereof, the patient following the administration having improved ejection fraction and fraction shortening as measured by echocardiography.
16. The method of claim 15 , wherein the therapeutically effective amount is about 15 mg/kg/day.
17. The method of claim 15 , wherein the therapeutically effective amount is about 30 mg/kg/day.
18. The method of claim 15 , wherein the administration has a duration of at least about eight weeks.